A Randomized Phase II Study of BAY 43-9006 in Combination With Gemcitabine in Metastatic Pancreatic Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2016
At a glance
- Drugs Gemcitabine (Primary) ; Sorafenib (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 22 Mar 2011 Results published in Investigational New Drugs.
- 12 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History